Get the Stockscreener App
82.90
0.53%
-0.44
After Hours:
82.90
Nuvalent Inc Stock (NUVL) Latest News
10 Mid-Cap Stocks Insiders Are Selling Recently - Insider Monkey
Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently - Insider Monkey
KBC Group NV Boosts Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
What is Leerink Partnrs’ Forecast for Nuvalent Q2 Earnings? - Defense World
Long Term Trading Analysis for (NUVL) - Stock Traders Daily
Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
The Potential Rise in the Price of Nuvalent Inc (NUVL) following insiders activity - Knox Daily
Nuvalent Inc (NUVL) is looking forward to a strong quarter - SETE News
Top 10 Takeover Targets of 2025 - Genetic Engineering & Biotechnology News
Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $165,580.00 in Stock - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Raised by SG Americas Securities LLC - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Nuvalent Inc Shares - GuruFocus.com
Nuvalent director Matthew Shair sells shares worth $165,575 - MSN
Nuvalent director Matthew Shair sells shares worth $165,575 By Investing.com - Investing.com Canada
How To Trade (NUVL) - news.stocktradersdaily.com
Bullish Two Hundred Day Moving Average CrossNUVL - Nasdaq
Nuvalent: A First Look (NASDAQ:NUVL) - Seeking Alpha
Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Nuvalent’s (NUVL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Nuvalent stock reiterates buy rating on FDA approval potential - MSN
Nuvalent CEO Porter James Richard sells shares worth $2.05m - MSN
JPMorgan Chase & Co. Has $3.55 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter Sells 27,000 Shares - MarketBeat
Nuvalent CEO Porter James Richard sells shares worth $2.05m By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Nuvalent stock reiterates buy rating on FDA approval potential By Investing.com - Investing.com Canada
Nuvalent's SWOT analysis: biotech stock shows promise amid clinical progress - Investing.com Canada
(NUVL) Trading Report - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent Announces Corporate Updates and Anticipated Milestones for 2025 - Defense World
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks - Investing.com Australia
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks By Investing.com - Investing.com South Africa
Nuvalent’s (NUVL) Outperform Rating Reaffirmed at Wedbush - Defense World
Nuvalent (NASDAQ:NUVL) Given "Outperform" Rating at Wedbush - MarketBeat
Nuvalent chief legal officer sells shares worth $236,182 By Investing.com - Investing.com Nigeria
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones - Yahoo Finance
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipate - GuruFocus.com
Nuvalent To Share Updated Data From ARROS-1, ALKOVE-1 Trials In September - RTTNews
Nuvalent: A Logical Acquisition Target (NASDAQ:NUVL) - Seeking Alpha
Nuvalent's chief development officer sells shares worth $320,009 By Investing.com - Investing.com Australia
Nuvalent's chief development officer sells shares worth $320,009 - Investing.com India
Nuvalent chief scientific officer sells shares worth $197,853 - Investing.com India
Nuvalent chief scientific officer sells shares worth $197,853 By Investing.com - Investing.com Canada
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):